[{"id":"a01c1d5f-e2a9-42b3-82b6-70a6e6b04112","acronym":"AALL1131","url":"https://clinicaltrials.gov/study/NCT02883049","created_at":"2021-01-18T14:09:12.849Z","updated_at":"2025-02-25T13:39:22.892Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","source_id_and_acronym":"NCT02883049 - AALL1131","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • RUNX1 • KMT2A • ETV6","pipe":" | ","alterations":" MLL rearrangement","tags":["ABL1 • BCR • RUNX1 • KMT2A • ETV6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5949","initiation":"Initiation: 02/29/2012","start_date":" 02/29/2012","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 10/03/2025","study_completion_date":" 10/03/2025","last_update_posted":"2025-02-21"},{"id":"91e34a00-0291-46e3-8305-1607660e8c78","acronym":"","url":"https://clinicaltrials.gov/study/NCT04994808","created_at":"2021-08-06T12:53:07.543Z","updated_at":"2025-02-25T16:45:30.587Z","phase":"Phase 2","brief_title":"Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia","source_id_and_acronym":"NCT04994808","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clofarabine • fludarabine IV • busulfan • Grafapex (treosulfan)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/11/2023","start_date":" 08/11/2023","primary_txt":" Primary completion: 10/03/2026","primary_completion_date":" 10/03/2026","study_txt":" Completion: 04/03/2027","study_completion_date":" 04/03/2027","last_update_posted":"2025-02-05"},{"id":"75104445-162f-444f-84ea-8038034ab832","acronym":"","url":"https://clinicaltrials.gov/study/NCT02727803","created_at":"2021-01-18T13:21:10.406Z","updated_at":"2024-07-02T16:34:36.895Z","phase":"Phase 2","brief_title":"Personalized NK Cell Therapy in CBT","source_id_and_acronym":"NCT02727803","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • BCL2","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • clofarabine • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • busulfan • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/19/2016","start_date":" 05/19/2016","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-06-10"},{"id":"9209a8c3-cb61-49cb-9b57-ded111720987","acronym":"","url":"https://clinicaltrials.gov/study/NCT01701986","created_at":"2021-01-18T07:24:10.982Z","updated_at":"2024-07-02T16:34:37.196Z","phase":"Phase 1/2","brief_title":"Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma","source_id_and_acronym":"NCT01701986","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • clofarabine • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • busulfan • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 10/25/2012","start_date":" 10/25/2012","primary_txt":" Primary completion: 06/05/2024","primary_completion_date":" 06/05/2024","study_txt":" Completion: 06/05/2024","study_completion_date":" 06/05/2024","last_update_posted":"2024-06-07"},{"id":"34e695f6-dbe3-425d-b9ce-de960e381284","acronym":"","url":"https://clinicaltrials.gov/study/NCT04644016","created_at":"2021-01-19T20:39:14.570Z","updated_at":"2024-07-02T16:35:01.196Z","phase":"Phase 2","brief_title":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","source_id_and_acronym":"NCT04644016","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clofarabine • fludarabine IV • busulfan • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 11/20/2020","start_date":" 11/20/2020","primary_txt":" Primary completion: 12/20/2025","primary_completion_date":" 12/20/2025","study_txt":" Completion: 12/20/2025","study_completion_date":" 12/20/2025","last_update_posted":"2024-05-24"},{"id":"da79fe71-e09f-48b0-9ffb-5c6b712e843b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05569512","created_at":"2022-10-06T13:55:46.803Z","updated_at":"2024-07-02T16:35:06.360Z","phase":"Phase 1/2","brief_title":"Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML","source_id_and_acronym":"NCT05569512","lead_sponsor":"Malika Kapadia","biomarkers":" RUNX1 • HLA-DRB1","pipe":" | ","alterations":" RUNX1 mutation","tags":["RUNX1 • HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clofarabine • fludarabine IV • busulfan • uproleselan (APL-106)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/06/2022","start_date":" 10/06/2022","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-05-02"},{"id":"d9205d85-be27-4b6c-84a5-c85c6627b25a","acronym":"NCI-2018-01198","url":"https://clinicaltrials.gov/study/NCT03136146","created_at":"2021-01-18T15:27:28.397Z","updated_at":"2024-07-02T16:35:12.329Z","phase":"Phase 2","brief_title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","source_id_and_acronym":"NCT03136146 - NCI-2018-01198","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib • cyclophosphamide • etoposide IV • clofarabine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • Marqibo (vincristine liposomal) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 08/09/2017","start_date":" 08/09/2017","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-03-29"},{"id":"4211f101-f1d0-468e-8f27-160ea15704ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT01885689","created_at":"2022-01-21T21:57:48.003Z","updated_at":"2024-07-02T16:35:14.418Z","phase":"Phase 2","brief_title":"Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT01885689","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • clofarabine • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 02/10/2014","start_date":" 02/10/2014","primary_txt":" Primary completion: 12/27/2019","primary_completion_date":" 12/27/2019","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-03-15"},{"id":"6d194b66-a36a-4049-9be1-f272a6096889","acronym":"","url":"https://clinicaltrials.gov/study/NCT03117751","created_at":"2021-01-18T15:21:39.440Z","updated_at":"2024-07-02T16:35:16.300Z","phase":"Phase 2/3","brief_title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","source_id_and_acronym":"NCT03117751","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" BCL2 • CEP72","pipe":"","alterations":" ","tags":["BCL2 • CEP72"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • bortezomib • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • Blincyto (blinatumomab) • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • Zolinza (vorinostat) • clofarabine • idarubicin hydrochloride • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • nelarabine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Erwinase (erwinia asparaginase) • Purixan (mercaptopurine oral suspension) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 790","initiation":"Initiation: 03/29/2017","start_date":" 03/29/2017","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2024-03-05"},{"id":"d88c1ac7-6c49-4687-9631-89d59339a7df","acronym":"","url":"https://clinicaltrials.gov/study/NCT04990323","created_at":"2021-08-04T13:53:03.286Z","updated_at":"2024-07-02T16:35:18.901Z","phase":"Phase 1/2","brief_title":"US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies","source_id_and_acronym":"NCT04990323","lead_sponsor":"ExCellThera inc.","biomarkers":" HLA-DRB1 • CD34","pipe":"","alterations":" ","tags":["HLA-DRB1 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • clofarabine • fludarabine IV • thiotepa • busulfan • Zemcelpro (dorocubicel) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-02-19"},{"id":"4ce913fc-70e5-4eaa-bf17-ac87c5e8708f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04220008","created_at":"2021-01-18T20:32:29.778Z","updated_at":"2024-07-02T16:35:23.576Z","phase":"Phase 2","brief_title":"Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04220008","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • cyclophosphamide • Zolinza (vorinostat) • clofarabine • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • busulfan • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/29/2021","start_date":" 10/29/2021","primary_txt":" Primary completion: 10/29/2021","primary_completion_date":" 10/29/2021","study_txt":" Completion: 10/29/2021","study_completion_date":" 10/29/2021","last_update_posted":"2024-01-12"},{"id":"76db4819-1806-4f6d-8363-46b52b7992fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT03096782","created_at":"2021-01-18T15:15:32.124Z","updated_at":"2024-07-02T16:35:33.856Z","phase":"Phase 2","brief_title":"Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma","source_id_and_acronym":"NCT03096782","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • clofarabine • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • busulfan • GB241 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 10/13/2017","start_date":" 10/13/2017","primary_txt":" Primary completion: 09/20/2022","primary_completion_date":" 09/20/2022","study_txt":" Completion: 09/20/2022","study_completion_date":" 09/20/2022","last_update_posted":"2023-10-11"},{"id":"b36bc5d7-36a7-42a7-bb53-a6578b4c6abc","acronym":"E2906","url":"https://clinicaltrials.gov/study/NCT02085408","created_at":"2021-01-18T09:36:49.162Z","updated_at":"2024-07-02T16:35:44.295Z","phase":"Phase 3","brief_title":"Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT02085408 - E2906","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • decitabine • daunorubicin • clofarabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 727","initiation":"Initiation: 02/04/2011","start_date":" 02/04/2011","primary_txt":" Primary completion: 02/22/2021","primary_completion_date":" 02/22/2021","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-06-30"},{"id":"3e7e11e0-cc11-423c-8060-72323bcbcf89","acronym":"","url":"https://clinicaltrials.gov/study/NCT00641030","created_at":"2021-01-18T02:23:08.219Z","updated_at":"2024-07-02T16:35:45.545Z","phase":"Phase 1","brief_title":"Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes","source_id_and_acronym":"NCT00641030","lead_sponsor":"City of Hope Medical Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clofarabine • melphalan"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2007","start_date":" 07/01/2007","primary_txt":" Primary completion: 01/01/2011","primary_completion_date":" 01/01/2011","study_txt":" Completion: 01/01/2011","study_completion_date":" 01/01/2011","last_update_posted":"2023-06-15"},{"id":"7acaf31c-df41-4b59-9766-7689b8426466","acronym":"","url":"https://clinicaltrials.gov/study/NCT00423514","created_at":"2021-01-18T01:29:23.216Z","updated_at":"2024-07-02T16:35:58.519Z","phase":"Phase 1/2","brief_title":"Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease","source_id_and_acronym":"NCT00423514","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clofarabine • melphalan • thiotepa • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 11/20/2006","start_date":" 11/20/2006","primary_txt":" Primary completion: 06/18/2021","primary_completion_date":" 06/18/2021","study_txt":" Completion: 06/18/2021","study_completion_date":" 06/18/2021","last_update_posted":"2022-12-26"},{"id":"faa98ffb-1b2f-4cb8-be4c-153dab662a50","acronym":"SCRIPT-AML","url":"https://clinicaltrials.gov/study/NCT05477589","created_at":"2022-07-28T14:55:32.252Z","updated_at":"2024-07-02T16:35:58.938Z","phase":"Phase 3","brief_title":"Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML","source_id_and_acronym":"NCT05477589 - SCRIPT-AML","lead_sponsor":"Vastra Gotaland Region","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • clofarabine • melphalan • fludarabine IV • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 06/07/2022","start_date":" 06/07/2022","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2031","study_completion_date":" 12/31/2031","last_update_posted":"2022-12-19"},{"id":"d5f97284-f241-4922-aff7-91252d0fa774","acronym":"","url":"https://clinicaltrials.gov/study/NCT01700946","created_at":"2021-01-18T07:23:42.396Z","updated_at":"2024-07-02T16:36:03.318Z","phase":"Phase 2","brief_title":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","source_id_and_acronym":"NCT01700946","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • etoposide IV • methotrexate • vincristine • clofarabine • mitoxantrone • Oncaspar liquid (pegaspargase) • Vumon (teniposide) • mercaptopurine • vinblastine • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 04/15/2013","start_date":" 04/15/2013","primary_txt":" Primary completion: 07/24/2021","primary_completion_date":" 07/24/2021","study_txt":" Completion: 07/24/2021","study_completion_date":" 07/24/2021","last_update_posted":"2022-09-28"},{"id":"03f05543-0558-4406-af40-e682d4bba542","acronym":"","url":"https://clinicaltrials.gov/study/NCT01119066","created_at":"2021-01-18T04:26:17.749Z","updated_at":"2024-07-02T16:36:05.975Z","phase":"Phase 2","brief_title":"HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies","source_id_and_acronym":"NCT01119066","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":" | ","alterations":" Chr t(4;14) • Chr t(14;16) • Chr t(15;17)","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(4;14) • Chr t(14;16) • Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • clofarabine • melphalan • fludarabine IV • thiotepa • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 422","initiation":"Initiation: 05/03/2010","start_date":" 05/03/2010","primary_txt":" Primary completion: 03/30/2021","primary_completion_date":" 03/30/2021","study_txt":" Completion: 03/30/2021","study_completion_date":" 03/30/2021","last_update_posted":"2022-08-05"},{"id":"3f0bae0c-93e6-47e0-8432-6e4185300c3f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01252667","created_at":"2021-01-18T05:02:56.602Z","updated_at":"2024-07-02T16:36:45.961Z","phase":"Phase 2","brief_title":"Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant","source_id_and_acronym":"NCT01252667","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clofarabine • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 01/25/2011","start_date":" 01/25/2011","primary_txt":" Primary completion: 01/25/2019","primary_completion_date":" 01/25/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2020-04-16"},{"id":"955ade7e-43c2-4214-a30a-5a0ead38156d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00498316","created_at":"2021-01-18T01:46:59.925Z","updated_at":"2024-07-02T16:36:49.427Z","phase":"Phase 1","brief_title":"Cord Blood Expansion on Mesenchymal Stem Cells","source_id_and_acronym":"NCT00498316","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • clofarabine • melphalan • fludarabine IV • busulfan • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 98","initiation":"Initiation: 07/03/2007","start_date":" 07/03/2007","primary_txt":" Primary completion: 10/01/2016","primary_completion_date":" 10/01/2016","study_txt":" Completion: 10/01/2016","study_completion_date":" 10/01/2016","last_update_posted":"2020-02-28"},{"id":"ced9bc0e-29ae-4948-8e4a-05fa8abeddb9","acronym":"AALL1131","url":"https://clinicaltrials.gov/study/NCT01406756","created_at":"2021-01-18T05:47:00.296Z","updated_at":"2024-07-02T16:37:15.546Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT01406756 - AALL1131","lead_sponsor":"Children's Oncology Group","biomarkers":" ABL1 • BCR • RUNX1 • KMT2A • ETV6","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["ABL1 • BCR • RUNX1 • KMT2A • ETV6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • prednisone • dexamethasone • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methylprednisolone sodium succinate"],"overall_status":"Recruiting","enrollment":" Enrollment 4895","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":"","study_completion_date":"","last_update_posted":"2017-12-13"},{"id":"5d967763-a9a0-47a7-8409-811f7afd860a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01041703","created_at":"2021-01-18T04:05:21.012Z","updated_at":"2024-07-02T16:37:15.691Z","phase":"Phase 3","brief_title":"Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT01041703","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • decitabine • daunorubicin • clofarabine"],"overall_status":"Recruiting","enrollment":" Enrollment 747","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 02/01/2019","primary_completion_date":" 02/01/2019","study_txt":"","study_completion_date":"","last_update_posted":"2017-12-08"},{"id":"4bd01e86-9ffb-411f-9165-4072db7ee2a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00201669","created_at":"2021-01-18T00:41:10.768Z","updated_at":"2024-07-02T16:37:15.769Z","phase":"Phase 2","brief_title":"A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00201669","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" TP53 • IL6 • TNFA • IL10","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • IL6 • TNFA • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clofarabine"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 10/01/2004","start_date":" 10/01/2004","primary_txt":" Primary completion: 05/01/2006","primary_completion_date":" 05/01/2006","study_txt":" Completion: 06/01/2006","study_completion_date":" 06/01/2006","last_update_posted":"2017-12-06"},{"id":"8b50b7e9-7468-4a63-8f8b-5dddd813e679","acronym":"","url":"https://clinicaltrials.gov/study/NCT00945815","created_at":"2021-01-18T03:40:26.168Z","updated_at":"2024-07-02T16:37:16.636Z","phase":"Phase 2","brief_title":"S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00945815","lead_sponsor":"Southwest Oncology Group","biomarkers":" CD22 • CD33 • CD4 • ANPEP","pipe":"","alterations":" ","tags":["CD22 • CD33 • CD4 • ANPEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • clofarabine • Epratucyn (epratuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 03/01/2013","primary_completion_date":" 03/01/2013","study_txt":" Completion: 08/01/2017","study_completion_date":" 08/01/2017","last_update_posted":"2017-11-06"}]